

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/251140 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *C12N 15/09* (2006.01)
C12N 1/21 (2006.01) *A61K 39/395* (2006.01)
A61P 37/02 (2006.01) *C12N 1/15* (2006.01)
C12N 1/19 (2006.01) *A61K 47/50* (2017.01)
A61P 35/00 (2006.01) *C12N 15/13* (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/CN2024/097464

(22) International Filing Date:

05 June 2024 (05.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/098574

06 June 2023 (06.06.2023) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth A91 X56F (IE).

(72) Inventors: **YANG, Baotian**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **ZHENG, Yong**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **LUO, Fangfang**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

LIANG, Zhongshuang; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CHEN, Haiqing**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **NIE, Siwei**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **GU, Jijie**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Xicheng District, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-TIGIT ANTIBODIES AND USES THEREOF




Figure 13

(57) Abstract: Provided are anti-TIGIT antibodies, the nucleic acid molecules encoding the anti-TIGIT antibodies, expression vectors and host cells used for the expression of anti-TIGIT antibodies. Further provides the methods for preventing and treating cancers and immune disorders by administering the anti-TIGIT antibodies.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*